SOURCE: iBio, Inc.

iBio, Inc.

November 10, 2014 08:31 ET

iBio Grants Caliber License for Production of Antibodies Targeting Ebola

NEWARK, DE--(Marketwired - Nov 10, 2014) - iBio, Inc. (NYSE MKT: IBIO) and Caliber Biotherapeutics LLC executed an agreement, effective today, for an emergency use license to the iBioLaunch™ platform for production by Caliber of antibodies that target the Ebola virus.

As previously announced on January 15 and October 16, 2014, iBio and Caliber have had an ongoing collaborative relationship reflected by a License and Collaboration Agreement dated February 14, 2013. Since early September, both iBio and Caliber have been examining how they could use their technologies and facilities to assist governments to address the Ebola epidemic.

The license announced today expands Caliber's freedom to operate under iBio's issued U.S. patents and related intellectual property to enable Caliber to assist the U.S. government by manufacturing certain experimental drugs that address the current Ebola virus outbreak, to the extent such assistance is requested. Caliber operates the largest capacity cGMP manufacturing facility in the world capable to use iBio's technology for the production of monoclonal antibodies, other biotherapeutics, and vaccines. 

On October 16, the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. government issued a Task Order Request to three pre-existing BARDA contractors, public-private consortia referred to as Centers for Innovation in Advanced Development and Manufacturing, for the procurement of a specified experimental Ebola therapeutic known as ZMapp™ made in Nicotiana plants. The submission deadline is November 10. None of the three consortia appears to have a plant-made pharmaceutical (PMP) technology or facility to produce significant quantities of the ZMapp experimental product in plants, so it is expected that the consortia interested to be involved will contract with PMP-capable parties in order to satisfy BARDA's requirements.

In addition to the Ebola-related activities, iBio and Caliber also are collaborating on commercial opportunities for recombinant antibodies and antibody-related proteins that can benefit from the speed, efficiency, and cost advantages of producing pharmaceutical proteins in plants instead of with bioreactor-based manufacturing methods such as those which use Chinese hamster ovary (CHO) cells. According to peer-reviewed, published scientific data, recombinant antibodies produced in plants can provide significant efficacy advantages over similar antibodies produced in CHO cells. The companies are evaluating both proprietary and biosimilar products for a variety of markets.

About iBio, Inc.

iBio owns the iBioLaunch™ platform, which is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. iBio is developing a proprietary product for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases using its iBioLaunch platform. The company also offers technology licenses to others and provides collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology. Further information is available at: www.ibioinc.com.

FORWARD-LOOKING STATEMENTS

STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

Contact Information

  • Investor Relations Contact

    Ron Both
    Liolios Group, Inc.
    Tel 949-574-3860
    Email Contact